BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ridaforolimus regulatory update

EMA accepted for review an MAA from Merck for ridaforolimus to treat metastatic sarcomas. The acceptance triggers a $25 million milestone payment to Ariad, from which Merck...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >